Strategic Partnerships Orexigen has successfully established collaborations with major pharmaceutical companies like Takeda, enhancing its product development and market reach. This indicates openness to joint ventures and licensing agreements, providing potential avenues for sales collaborations and co-marketing opportunities.

Innovative Product Portfolio The company's focus on weight management medications such as Contrave and Mysimba, supported by recent campaigns and legal wins, suggests ongoing demand in the obesity and metabolic disorder markets. Targeting healthcare providers and clinics specializing in weight management could be a fruitful sales approach.

Financial and R&D Investment With substantial funding of $165M and a revenue range of $25M to $50M, Orexigen demonstrates significant financial backing and commitment to product development. This presents opportunities to offer advanced technologies, clinical solutions, or services that support their innovation-driven growth.

Legal and Patent Focus The company’s active engagement in patent litigation and defending IP rights highlights their emphasis on protecting innovative formulations. Sales prospects may include legal services, intellectual property management, or compliance solutions tailored for pharmaceutical firms.

Market Expansion Potential Recent licensing agreements for the UK and Ireland signal a strategy to expand commercial footprints. Engaging with local distributors, healthcare networks, and digital marketing solutions could further accelerate their market penetration and sales channels globally.